Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cystic fibrosis treatment: Triple combination benefits patients with advanced disease

Publish date:: November 5, 2020

Key clinical point: Patients with advanced disease benefited from triple combination therapy.

Major finding: Patients’ ppFEV₁ value increased by a mean of 7.8%.

Study details: Retrospective analysis (n = 68).

Disclosures: The study received funding from the Cystic Fibrosis Foundation and Dartmouth College. Dr. Bermingham and Dr. Giusti have no relevant financial disclosures.

Citation:

Bermingham B. et al. NACFC 2020, Abstract 645.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Pulmonology

E-cigarette use tied to increased COPD, asthma risk,

Obesity, hypoxia predict severity in children with COVID-19,

Telehealth finds acceptance among patients with CF, clinicians,

COVID-19 burdens follow patients after discharge,

Poverty raises depression risk in patients with cystic fibrosis,